Literature DB >> 9152382

gamma-Hydroxybutyrate conversion into GABA induces displacement of GABAB binding that is blocked by valproate and ethosuximide.

V Hechler1, C Ratomponirina, M Maitre.   

Abstract

gamma-Hydroxybutyrate (GHB) has been reported to be a ligand for GABAB receptor(s), although with low or very low affinity (IC50 = 150-796 microM). In addition, several reports argue for a role of GHB via GABAB receptors in both in vivo and in vitro electro-physiological experiments. In the present study, we demonstrate that the inhibition of GHB's conversion into GABA by rat brain membranes blocks the ability of GHB to interfere with GABAB binding. In particular, the inhibition of GHB dehydrogenase by valproate or ethosuximide and the blockade of GABA-T by aminooxyacetic acid induce the disappearance of the GABA-like effect of GHB at GABAB, but also at GABAA, receptors. This finding could explain the misinterpretation of in vitro or in vivo experiments where GHB possesses a GABA-like effect. But in addition, it is postulated that the normal metabolism of GHB in brain induces GABAB mechanisms that could be blocked by the administration of valproate or ethosuximide.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9152382

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

Review 1.  Unravelling the brain targets of gamma-hydroxybutyric acid.

Authors:  Vincenzo Crunelli; Zsuzsa Emri; Nathalie Leresche
Journal:  Curr Opin Pharmacol       Date:  2005-12-20       Impact factor: 5.547

2.  Concentration-effect relationships for the drug of abuse gamma-hydroxybutyric acid.

Authors:  Melanie A Felmlee; Samuel A Roiko; Bridget L Morse; Marilyn E Morris
Journal:  J Pharmacol Exp Ther       Date:  2010-03-09       Impact factor: 4.030

3.  Gamma-hydroxybutyrate (GHB) and topiramate--clinically relevant drug interaction suggested by a case of coma and increased plasma GHB concentration.

Authors:  Tobias Weiss; Daniel Müller; Isabelle Marti; Caroline Happold; Stefan Russmann
Journal:  Eur J Clin Pharmacol       Date:  2012-11-17       Impact factor: 2.953

4.  Mechanistic toxicokinetic model for gamma-hydroxybutyric acid: inhibition of active renal reabsorption as a potential therapeutic strategy.

Authors:  Melanie A Felmlee; Qi Wang; Dapeng Cui; Samuel A Roiko; Marilyn E Morris
Journal:  AAPS J       Date:  2010-05-12       Impact factor: 4.009

5.  Alterations in neuronal transport but not blood-brain barrier transport are observed during gamma-hydroxybutyrate (GHB) sedative/hypnotic tolerance.

Authors:  Indranil Bhattacharya; Joseph J Raybon; Kathleen M K Boje
Journal:  Pharm Res       Date:  2006-08-10       Impact factor: 4.200

6.  Effects of GABA agonists on body temperature regulation in GABA(B(1))-/- mice.

Authors:  Christophe Quéva; Marianne Bremner-Danielsen; Anders Edlund; A Jonas Ekstrand; Susanne Elg; Sven Erickson; Thore Johansson; Anders Lehmann; Jan P Mattsson
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

7.  Pathway-specific action of gamma-hydroxybutyric acid in sensory thalamus and its relevance to absence seizures.

Authors:  Nicolas Gervasi; Zohreh Monnier; Pierre Vincent; Daniele Paupardin-Tritsch; Stuart W Hughes; Vincenzo Crunelli; Nathalie Leresche
Journal:  J Neurosci       Date:  2003-12-10       Impact factor: 6.167

8.  Phenotypic and chemotypic studies using Arabidopsis and yeast reveal that GHB converts to SSA and induce toxicity.

Authors:  Dereje Worku Mekonnen; Frank Ludewig
Journal:  Plant Mol Biol       Date:  2016-04-01       Impact factor: 4.076

9.  Effects of gamma hydroxybutyric acid on inhibition and excitation in rat neocortex.

Authors:  Q Li; C M Kuhn; W A Wilson; D V Lewis
Journal:  Neuroscience       Date:  2007-08-28       Impact factor: 3.590

10.  Effects of L-lactate and D-mannitol on gamma-hydroxybutyrate toxicokinetics and toxicodynamics in rats.

Authors:  Qi Wang; Xiaodong Wang; Marilyn E Morris
Journal:  Drug Metab Dispos       Date:  2008-08-21       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.